J&J will proceed with a $2.3 billion takeover bid for Crucell

12/2/2010 | Wall Street Journal, The

Johnson & Johnson plans to go ahead with a $2.3 billion cash offer to acquire the rest of Crucell. The drug giant has left open a possibility for renegotiation in case the biotech firm's manufacturing problems in South Korea worsen. J&J expects Dutch regulators to decide on the transaction ahead of Crucell's shareholder meeting Dec. 10.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ